How facial type relates to relapse after orthodontic treatment during retention

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective interventional study examines how facial type (hyperdivergent vs. hypodivergent) influences relapse of dentition after active orthodontic treatment during the retention period. It uses three planes of space to analyze dental alignment changes and aims to identify whether horizontal and vertical growers show different relapse tendencies, particularly in overbite and mandibular incisor alignment. Participants will have completed orthodontic treatment, meet specific occlusal and health criteria, and will be followed to assess stability of outcomes. The study builds on retention theory and prior observations that growth and dental relapse contribute to post-treatment changes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Fixed orthodontic cases with FMA of 26 0 or more for hyperdivergent cases and FMA Of 24 o or less for hypodivergent cases.
* Optimal functional occlusion at end of treatment (PAR score \>70%).
* Littles irregularity index (Pre-treatment \<6mm in both upper and lower arch).
* Nonsurgical and non-orthopedic patients and non syndromic patients.
* Optimal periodontal condition and Good oral hygiene (probing depth \<3mm, gingival index score \<1
* Good compliance regarding retainer wear

Exclusion Criteria:

* Subjects with incomplete orthodontic treatment.
* TMJ disorder patients.
* Any systemic disease affecting bone and general growth.
* Patients with incomplete records
* Patient who fail to follow up or undergo complete treatment.
* Patient with learning difficulties
* Patients having antibiotic therapy within previous 3 months and used anti inflammatory drugs in the month before the study

Where it's running

• Dr.Manisha
  Rohtak, Haryana, India Recruiting

Study contacts

• Study coordinator: Dr Manisha kamal kukreja, MDS
• Email: mk3pgids@gmail.com
• Phone: 9215650617

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can a multi-omics and AI model predict ABPA relapse within 1 year in adults?

  This study tests a machine learning model that uses multi-omics and clinical data to predict the 1-year relapse risk for adults with ABPA who are in a stable state.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07611838

• Serplulimab plus second-line chemo/targeted therapy for early-relapse colorectal cancer after adjuvant therapy

  This trial tests whether adding serplulimab to standard second-line chemotherapy plus targeted therapy helps people whose colorectal cancer came back early after adjuvant treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07604909

• How iNKT immune cells after allogeneic stem cell transplant relate to transplant complications

  This study tests whether levels of invariant NKT cells in the blood after an allogeneic stem cell transplant can be linked to complications like GvHD, infections, or relapse in patients with AML.

  Recruiting University Hospital Pilsen · Pilsen, Czechia · NCT07570407

• Daratumumab for refractory aplastic anemia in adults

  This trial tests whether daratumumab can be safely given and help people with refractory aplastic anemia see a benefit.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07287228

• Blinatumomab plus donor lymphocyte infusion to prevent relapse after transplant in high-risk Ph-negative B‑cell ALL

  This trial tests whether giving blinatumomab together with donor lymphocyte infusions can help prevent relapse in people aged 14–65 with high‑risk Philadelphia chromosome–negative B‑cell acute lymphoblastic leukemia after an allogeneic stem cell transplant.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou · NCT07105579

• Epcoritamab plus loncastuximab tesirine for relapsed or refractory large B-cell lymphoma

  This test gives epcoritamab together with loncastuximab tesirine to adults whose large B-cell lymphoma has come back or not responded, to see if it can shrink or clear the cancer.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06919939

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.